JP2024541900A - がんの治療のためのエンドキシフェン - Google Patents

がんの治療のためのエンドキシフェン Download PDF

Info

Publication number
JP2024541900A
JP2024541900A JP2024524402A JP2024524402A JP2024541900A JP 2024541900 A JP2024541900 A JP 2024541900A JP 2024524402 A JP2024524402 A JP 2024524402A JP 2024524402 A JP2024524402 A JP 2024524402A JP 2024541900 A JP2024541900 A JP 2024541900A
Authority
JP
Japan
Prior art keywords
cancer
endoxifen
subject
response
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541900A5 (cg-RX-API-DMAC7.html
Inventor
スティーブン シー. キー,
カーラ グランドリ,
カタニヤ カペリ,
Original Assignee
アトッサ・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトッサ・セラピューティクス・インコーポレイテッド filed Critical アトッサ・セラピューティクス・インコーポレイテッド
Publication of JP2024541900A publication Critical patent/JP2024541900A/ja
Publication of JP2024541900A5 publication Critical patent/JP2024541900A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024524402A 2021-10-28 2022-10-27 がんの治療のためのエンドキシフェン Pending JP2024541900A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272869P 2021-10-28 2021-10-28
US63/272,869 2021-10-28
PCT/US2022/048061 WO2023076496A1 (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Publications (2)

Publication Number Publication Date
JP2024541900A true JP2024541900A (ja) 2024-11-13
JP2024541900A5 JP2024541900A5 (cg-RX-API-DMAC7.html) 2025-11-17

Family

ID=86158538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524402A Pending JP2024541900A (ja) 2021-10-28 2022-10-27 がんの治療のためのエンドキシフェン

Country Status (10)

Country Link
US (1) US20250041245A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422608A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024541900A (cg-RX-API-DMAC7.html)
KR (1) KR20240093500A (cg-RX-API-DMAC7.html)
CN (1) CN118159259A (cg-RX-API-DMAC7.html)
AU (1) AU2022378576A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232972A1 (cg-RX-API-DMAC7.html)
IL (1) IL312037A (cg-RX-API-DMAC7.html)
MX (1) MX2024005220A (cg-RX-API-DMAC7.html)
WO (1) WO2023076496A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
CN117338780A (zh) * 2023-09-21 2024-01-05 中国人民解放军海军军医大学 帕罗西汀在制备抗肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
CN104334170B (zh) * 2011-11-04 2020-02-07 迈伦·R·谢夫丘克 Neu1唾液酸酶抑制剂在癌症治疗中的用途
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CA3160614A1 (en) * 2019-12-12 2021-06-17 Marcela GUZMAN AYALA Method and compositions for regulated armoring of cells
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
EP4514327A1 (en) * 2022-04-26 2025-03-05 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use

Also Published As

Publication number Publication date
IL312037A (en) 2024-06-01
EP4422608A4 (en) 2025-09-24
AU2022378576A1 (en) 2024-03-28
KR20240093500A (ko) 2024-06-24
EP4422608A1 (en) 2024-09-04
US20250041245A1 (en) 2025-02-06
WO2023076496A1 (en) 2023-05-04
CN118159259A (zh) 2024-06-07
MX2024005220A (es) 2024-05-16
CA3232972A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
US12281056B2 (en) Methods for making and using endoxifen
US20250041245A1 (en) Endoxifen for treatment of cancers
TW202340135A (zh) (z)—因多昔芬之組合物及其富集方法
US20250281414A1 (en) High dose endoxifen formulations and methods of use
WO2022192488A1 (en) Endoxifen for treatment of ovarian cancer
HK40105626A (en) Endoxifen for treatment of cancers
WO2024091551A1 (en) Crystalline forms, pharmaceutical compositions and methods of use thereof
Chen et al. Targeted Cancer Therapies, from Small Molecules to Antibodies
WO2026101937A1 (en) Compositions comprising (z)-endoxifen and a cdk4/6 inhibitor and methods of use thereof
WO2026097103A2 (en) Method of improving breast health management
JP2025506691A (ja) がんを処置する際に使用するためのoxphos阻害剤
HK40031003A (en) Methods for making and using endoxifen

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107